Hyperamylasemia During Omalizumab Therapy

OZTURK AKTAS, OZGE; KARAKAYA, GÜL; Kalyoncu, Ali Fuat; karabiber, esra; Özdemir, Ebru; Damadoglu, Ebru; SAHINER, Umit

doi:10.21911/aai.650

Hyperamylasemia During Omalizumab Therapy

Esra KARABİBER, (Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi İmmünoloji ve Alerji Hastalıkları Kliniği, İstanbul, Türkiye)

Özge ÖZTÜRK AKTAŞ, (Ankara Şehir Hastanesi İmmünoloji ve Allerji Kliniği, Ankara, Türkiye)

Ebru Özdemir, (Malatya Eğitim ve Araştırma Hastanesi İmmünoloji ve Alerji Kliniği, Malatya, Türkiye)

Ebru ÇELEBİOĞLU, (Hacettepe Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Ümit Murat ŞAHINER, (Hacettepe Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Gül KARAKAYA, (Hacettepe Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Ali Fuat KALYONCU (Hacettepe Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Astım Allerji İmmünoloji

10 2

Yıl: 2022 Cilt: 20 Sayı: 1 Sayfa Aralığı: 31 - 35 Metin Dili: İngilizce DOI: 10.21911/aai.650 İndeks Tarihi: 13-05-2023

Hyperamylasemia During Omalizumab Therapy

Öz:

Objective: Omalizumab safety studies have shown that the drug has an excellent safety profile and is well tolerated in patients with asthma and chronic idiopatic urticaria (CIU) with no blood chemistry monitoring during treatment. Although our clinical experience with drug has pointed out abnormalities in amylase levels. The aim of the present study is to assess blood amylase values during omalizumab therapy and to explain if there is an association between omalizumab therapy and high serum amylase levels. Materials and Methods: Patients who received omalizumab therapy for severe persistent allergic asthma or CIU between November 2015 and December 2016 were included in the study. Complete blood counts and biochemistry including liver function tests, amylase, pancreatic amylase, and lipase blood levels were evaluated at basal and every visit before omalizumab administration. Patients were evaluated at the time of injection visits that were scheduled every 2 to 4 weeks based on omalizumab dosage. Laboratory assessments followed up at least 1 month to one year. Patients that developed persistent hyperamylasemia carried on with further diagnostic work-up. Results: Of the total 76 patients, 59 (77.6%) had a diagnosis of CIU and 17 (22.4%) had severe persistent allergic asthma. The median cumulative dose of omalizumab was 4350 (range 900-36000) mg. In the follow-up period, at least one high amylase level was observed in 17 (22.4%) patients. Of these, 11 patients had transient amylase elevation, which returned to the normal range during follow-up. The remaining 6 patients had persistent amylase elevation and underwent further diagnostic examinations. Macroamylasemia was considered as a differential diagnosis and one patient had laboratory tests for macroamylasemia but the results were found within normal limits. There was no statistically significant difference between patients with transient and persistent amylase elevation compared with patients with normal amylase levels in terms of disease, duration of disease, duration of treatment, omalizumab cumulative dose, age, body mass index, and alcohol consumption. Conclusion: Hyperamylasemia associated with omalizumab therapy is not clear, on the other hand it is a diagnosis of exclusion and all other probable causes of hyperamylasemia were sufficiently excluded. Physicians should be aware of elevated amylase levels in patients treated with omalizumab. To preclude confusion on hyperamylasemia in patients who receive omalizumab, we recommend assessing baseline levels of amylase to clarify if omalizumab causes hyperamylasemia in the treatment period.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Babu KS, Arshad SH, Holgate ST. Anti-IgE treatment: An update. Allergy 2001;56:1121-8.
2. Belliveau PP. Omalizumab: A monoclonal anti-IgE antibody. Med Gen Med 2005;7:27.
3. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe asthma. J Allergy Clin Immunol 2001;108:184-90.
4. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154-9.
5. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2):E36.
6. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003;91:182-8.
7. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis. A randomized controlled trial. JAMA 2001;286:2956- 67.
8. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-9.
9. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:160-7.
10. Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler- Taylor A, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24(5):323-9.
11. Bekçibaşı M, Barutçu S, Çelen MK, Dayan S, Hoşoğlu S. Churg- Strauss syndrome occurring during omalizumab treatment. Eur J Rheumatol 2015;2(3):129-30.
12. Nazir S, Tachamo N, Fareedy SB, Khan MS, Lohani S. Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ann Allergy Asthma Immunol 2017;118(3):372-4.
13. Yung S, Han D, Lee JK. Cutaneous sarcoidosis in a patient with severe asthma treated with omalizumab. Can Respir J 2015;22(6):315-6.
14. Xolairhcp. Access date: 2021. Available from: https://www. xolairhcp.com/
15. Borovickova I, Bhatt NR, Boran GP, Ridgway PF. Persistent chronic hyperamylasemia: Clinical interpretation and diagnostic approach. J Pancreas 2016;17:349-58.
16. Lawson GJ. Prevelance of macroamylasemia using polyethylene glycol precipitation as a screening method. Ann Clin Biochem 2001;38:37-45.
17. Scheutzel P, Gerlach U. Alpha-amylase isoenymes in serum and saliva of patients with anorexia and bulimia nervosa. Z Gastroenterol 1991;29:339-45.
18. Vissers RJ, Abu-Laban Rb, Mchugh DF. Amylase and lipase in the emergency department evaluation of acute pancreatitis. J Emerg Med 1999;17:1027-37.

APA	karabiber e, OZTURK AKTAS O, Özdemir E, Damadoglu E, SAHINER U, KARAKAYA G, Kalyoncu A (2022). Hyperamylasemia During Omalizumab Therapy. , 31 - 35. 10.21911/aai.650
Chicago	karabiber esra,OZTURK AKTAS OZGE,Özdemir Ebru,Damadoglu Ebru,SAHINER Umit,KARAKAYA GÜL,Kalyoncu Ali Fuat Hyperamylasemia During Omalizumab Therapy. (2022): 31 - 35. 10.21911/aai.650
MLA	karabiber esra,OZTURK AKTAS OZGE,Özdemir Ebru,Damadoglu Ebru,SAHINER Umit,KARAKAYA GÜL,Kalyoncu Ali Fuat Hyperamylasemia During Omalizumab Therapy. , 2022, ss.31 - 35. 10.21911/aai.650
AMA	karabiber e,OZTURK AKTAS O,Özdemir E,Damadoglu E,SAHINER U,KARAKAYA G,Kalyoncu A Hyperamylasemia During Omalizumab Therapy. . 2022; 31 - 35. 10.21911/aai.650
Vancouver	karabiber e,OZTURK AKTAS O,Özdemir E,Damadoglu E,SAHINER U,KARAKAYA G,Kalyoncu A Hyperamylasemia During Omalizumab Therapy. . 2022; 31 - 35. 10.21911/aai.650
IEEE	karabiber e,OZTURK AKTAS O,Özdemir E,Damadoglu E,SAHINER U,KARAKAYA G,Kalyoncu A "Hyperamylasemia During Omalizumab Therapy." , ss.31 - 35, 2022. 10.21911/aai.650
ISNAD	karabiber, esra vd. "Hyperamylasemia During Omalizumab Therapy". (2022), 31-35. https://doi.org/10.21911/aai.650

APA	karabiber e, OZTURK AKTAS O, Özdemir E, Damadoglu E, SAHINER U, KARAKAYA G, Kalyoncu A (2022). Hyperamylasemia During Omalizumab Therapy. Astım Allerji İmmünoloji, 20(1), 31 - 35. 10.21911/aai.650
Chicago	karabiber esra,OZTURK AKTAS OZGE,Özdemir Ebru,Damadoglu Ebru,SAHINER Umit,KARAKAYA GÜL,Kalyoncu Ali Fuat Hyperamylasemia During Omalizumab Therapy. Astım Allerji İmmünoloji 20, no.1 (2022): 31 - 35. 10.21911/aai.650
MLA	karabiber esra,OZTURK AKTAS OZGE,Özdemir Ebru,Damadoglu Ebru,SAHINER Umit,KARAKAYA GÜL,Kalyoncu Ali Fuat Hyperamylasemia During Omalizumab Therapy. Astım Allerji İmmünoloji, vol.20, no.1, 2022, ss.31 - 35. 10.21911/aai.650
AMA	karabiber e,OZTURK AKTAS O,Özdemir E,Damadoglu E,SAHINER U,KARAKAYA G,Kalyoncu A Hyperamylasemia During Omalizumab Therapy. Astım Allerji İmmünoloji. 2022; 20(1): 31 - 35. 10.21911/aai.650
Vancouver	karabiber e,OZTURK AKTAS O,Özdemir E,Damadoglu E,SAHINER U,KARAKAYA G,Kalyoncu A Hyperamylasemia During Omalizumab Therapy. Astım Allerji İmmünoloji. 2022; 20(1): 31 - 35. 10.21911/aai.650
IEEE	karabiber e,OZTURK AKTAS O,Özdemir E,Damadoglu E,SAHINER U,KARAKAYA G,Kalyoncu A "Hyperamylasemia During Omalizumab Therapy." Astım Allerji İmmünoloji, 20, ss.31 - 35, 2022. 10.21911/aai.650
ISNAD	karabiber, esra vd. "Hyperamylasemia During Omalizumab Therapy". Astım Allerji İmmünoloji 20/1 (2022), 31-35. https://doi.org/10.21911/aai.650